BMY
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company historical holders
total: 20
Wedgewood Partners Bristol-Myers Squibb Company transactions over time
- Total transactions:
- 14
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 9
- Held since:
- 2019 Q4
- Held for:
- 13 quarters
- Latest activity:
- 2023 Q1
David Rolfe has been an institutional investor in Bristol-Myers Squibb Company (BMY) since 2019 Q4. According to 2026 Q1 report, David Rolfe doesn't hold any shares. The fund/company first acquired BMY in 2019 Q4, initially purchasing 391,442 shares. Since the initial investment, Wedgewood Partners has made 13 more transactions in this position.
When did David Rolfe exit their BMY position?
David Rolfe no longer holds Bristol-Myers Squibb Company (BMY). They sold off their entire position in 2023 Q1, closing out an investment that began in 2019 Q4.
When did David Rolfe first invest in BMY?
David Rolfe first invested in Bristol-Myers Squibb Company (BMY) in 2019 Q4 at the reported quarter-end price of $64.19 per share, acquiring 391,442 shares in their initial purchase.
What is David Rolfe's average cost basis for BMY?
Based on historical transaction data, David Rolfe's estimated cost basis for Bristol-Myers Squibb Company (BMY) is approximately $62.70 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $62.70
- Weighted AVG sell price:
- $61.92
BMY transactions history by Wedgewood Partners
14 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q1
|
0.00%
|
0
|
$71.86
|
|
-100% (-4,175)
|
-0.06%
|
|
2022 Q4
|
0.06%
|
4,175
|
$71.86
|
$300,000
|
-23.04% (-1,250)
|
-0.02%
|
|
2022 Q3
|
0.07%
|
5,425
|
$70.97
|
$385,000
|
-8.44% (-500)
|
-0.01%
|
|
2022 Q2
|
0.08%
|
5,925
|
$76.96
|
$456,000
|
-14.44% (-1,000)
|
-0.01%
|
|
2022 Q1
|
0.07%
|
6,925
|
$72.92
|
$505,000
|
+48.13% (+2,250)
|
+0.02%
|
|
2021 Q4
|
0.04%
|
4,675
|
$62.25
|
$291,000
|
-11.79% (-625)
|
-0.01%
|
|
2021 Q3
|
0.04%
|
5,300
|
$59.06
|
$313,000
|
-5.78% (-325)
|
-0%
|
|
2021 Q2
|
0.05%
|
5,625
|
$66.67
|
$375,000
|
-92.58% (-70,210)
|
-0.72%
|
|
2021 Q1
|
0.74%
|
75,835
|
$63.12
|
$4,787,000
|
-81.68% (-338,222)
|
-3.18%
|
|
2020 Q4
|
3.82%
|
$62.03
|
-5.75% (-25,262)
|
|||
|
2020 Q3
|
4.19%
|
$60.29
|
+17.53% (+65,538)
|
|||
|
2020 Q2
|
3.72%
|
$58.80
|
+44.22% (+114,601)
|
|||
|
2020 Q1
|
2.74%
|
$55.74
|
-33.79% (-132,262)
|
|||
|
2019 Q4
|
2.55%
|
$64.19
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.